• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Ac­tive Biotech is back, with one last bid for the failed MS drug Te­va dis­card­ed

6 years ago
R&D

It's not just about Keytru­da, Mer­ck in­sists, as it carves out as­sets worth $6.5B in­to new com­pa­ny

6 years ago
Deals
R&D

Glax­o­SmithK­line's lat­est makeover in­cludes auc­tion­ing off der­ma­tol­ogy, adding new tech and lay­offs. But how many?

6 years ago
R&D

Chi­na re­searchers tout in vit­ro da­ta for Gilead­'s an­tivi­ral against Wuhan virus — which they are try­ing to patent

6 years ago
China

Yes, Gilead CEO Daniel O’Day is ready to ink some deals. No, you won’t see him sweat it

6 years ago
Bioregnum
R&D

French can­cer-fo­cused mi­cro­bio­me play­er is flush with €18M Se­ries B in­jec­tion

6 years ago
Financing

Bay Area biotech CEO con­vict­ed of si­phon­ing off $2.6M to buy a home; Mer­ck wins Alzheimer's nod for in­som­nia pill

6 years ago
News Briefing

The Sanofi-part­nered start­up find­ing clin­i­cal tri­als for the 90%

6 years ago
Financing
Startups

HIV vac­cine re­mains Holy Grail as Sanofi/GSK reg­i­men dis­ap­points in large study

6 years ago
R&D

Bio­Mo­tiv, Bris­tol-My­ers al­liance bears fruit with new com­pa­ny: An­teros Phar­ma

6 years ago
Deals
R&D

Re­gen­eron joins the hunt for an­ti­bod­ies to fight a brew­ing pan­dem­ic as re­searchers whip up new tri­als for an­tivi­rals

6 years ago
R&D

Too slow to warn: Sanofi in­dict­ed over old an­ti-epilep­tic drug tied to birth de­fects

6 years ago
Pharma
FDA+

Q&A with Jorge Conde as An­dreessen Horowitz launch­es $750M bio fund III

6 years ago
Financing

In­smed’s PhII smokes and sput­ters, but re­searchers her­ald enough sur­pris­ing­ly pos­i­tive da­ta to roar on Wall Street

6 years ago
R&D

Court sides with FDA in Van­da clin­i­cal hold suit

6 years ago
FDA+

F-Prime backs a niche AI soft­ware start­up hunt­ing lofty goals in $22M Se­ries B

6 years ago
Financing
Startups

How much does it cost to boot­strap a gene ther­a­py start­up? Not too much if you're Jim Wil­son, per Pas­sage Bio's $125M ...

6 years ago
Financing
Cell/Gene Tx

Failed piv­otal study? You can still have break­through ther­a­py sta­tus — FDA sig­nals to Resver­logix

6 years ago
R&D

Rev­o­lu­tion Med­i­cines shoots for $150 mil­lion IPO; No­var­tis vet heads to Boston Phar­ma

6 years ago
News Briefing

GAO re­port rais­es ques­tions about reau­tho­riz­ing two PRV pro­grams

6 years ago
FDA+

Pan­dem­ic fears force Chi­nese biotech to post­pone Hong Kong IPO meet­ings — Bloomberg

6 years ago
Financing
China

Unit­ed Ther­a­peu­tic­s' drug fails PhII/III can­cer tri­al, mark­ing their sec­ond straight stum­ble in post-Re­mod­ulin PAH

6 years ago
R&D

Roche vet San­dra Horn­ing jumps on bio­phar­ma board no. 3 — what’s that worth?

6 years ago
R&D

Catal­ent chief John Chimin­s­ki trig­gers a $315M-plus wa­ger on the boom­ing cell ther­a­py mar­ket now in the mak­ing

6 years ago
Deals
Outsourcing
First page Previous page 856857858859860861862 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.